arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

ABBOTT LABORATORIES

ABT
$107.81 ▼ -0.13 (-0.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
74 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Bullish
auto_awesome

Analytical Summary

ABBOTT LABORATORIES shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $187.9B
Dividend Yield 0.58%
Revenue Growth 7.8%
Op. Margin 12.0%
ROIC 1.2%
FCF / Share $0.53
Trailing P/E 173.9x
Price / Book 3.6x
FCF Yield 0.5%
Debt / Equity 0.57
info Valuation on last close. End-of-day price, Aug 7, 2026.

74-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.16B
↑ +7.8%
Net Income Profit after all expenses
$1.08B
↓ -18.7%
Operating Margin Operating profit as % of sales
12.0%
↓ -38.7% 72th
FCF / Share Free cash flow per share
$0.53
↓ -2.0%
Long-Term Debt Long-term obligations
$29.64B
↑ +129.2%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
74
Returns
75
Financial Health
77
Cash Quality
70

Dividend History

Dividend / share · sourced from SEC filings
$2.40 Latest / share
+7.1% YoY
+7.4% 3-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 20 years · 74 quarters